

Applicants: Jeremy Green et al.
Application No.: 10/808,678

REMARKS

The Claim Amendments

Claims 1-46, 48, 55, and 57-58 have been canceled.

Applicants have amended claim 47 to recite a pharmaceutical composition that includes a compound of formula I and a pharmaceutically acceptable carrier, adjuvant, or vehicle. Support for this amendment is found in paragraphs [0066] and [00136] on pages 18-21 and 46, respectively, of the specification.

Claims 50-51 have been amended to recite a method of inhibiting various protein kinases in various biological samples by a compound or composition of the invention. Support for this amendment is found in paragraph [00181] on page 61 of the specification.

Claims 52, 54, and 56 have been amended to recite methods of treating various cancers or proliferative diseases by a composition of the invention. Support for these amendments is found in the claims as originally filed and the corresponding specification text.

New claims 59-101 have been added. These claims recite a pharmaceutical composition that includes a compound of amended claim 47. Support for this amendment is found in paragraphs [0087]-[00121] on pages 31-42 of the specification.

None of the amendments contain new matter. Their entry is requested.

The Restriction

The Examiner has required a restriction in the above-identified application under 35 U.S.C. § 121 to one of the following five groups:

- I. Claims 1-46 (in part), drawn to compounds where T/A1/A2/A3 are all carbon, classified in class 549, subclass various;
- II. Claims 1-46 (in part), drawn to compounds where T is nitrogen and A1/A2/A3 are all carbon, classified in class 546, subclass various;

Applicants: Jeremy Green et al.
Application No.: 10/808,678

III. Claims 1-46 (in part), drawn to compounds where T is nitrogen and one of A1/A2/A3 is nitrogen, classified in class 544, subclass various;

IV. Claims 1-46 (in part), drawn to compounds not represented by the above groups, classified in class 544, 546, 549, subclass various; and


V. Claims 47-58, drawn to compositions and methods of use, classified in class 514, subclass various.

Applicants elect Group V without traverse.

The Election of Species

The Examiner has required an election of species under 35 U.S.C. § 121.

Applicants elect species I-12 without traverse.



Claims 47, 49-54, 56, 59-60, 62, 65-66, 68-75, 77, 81, 84, 87, 90-93, 96, and 99-101 read on the elected species.

The definitions of the substituents for a compound of formula I as they relate to compound I-12 are as follows: R¹ is -(L)_mAr¹, where m is 0 and Ar¹ is an optionally substituted 5-7 membered monocyclic ring substituted with up to 5 occurrences of Z-R^X, wherein R^X is -OR', where R' is an optionally substituted C₁₋₆ aliphatic group; R² is hydrogen; T is CR³, wherein R³ is hydrogen; A¹ is CR⁴, wherein R⁴ is halogen; A² is CR⁴, wherein R⁴ is -(L)_mR, where m is 0 and R is hydrogen; and A³ is CR⁴, wherein R⁴ is -(L)_mR, where m is 0 and R is hydrogen.

Applicants: Jeremy Green et al.
Application No.: 10/808,678

The elections made herein are made expressly without waiver of applicants' rights to continue to prosecute and to obtain claims to the non-elected subject matter either in this application or in other applications claiming benefit herefrom.

Conclusion

Applicants request that the Examiner enter the above amendments and allow the claims to pass to issue. Should the Examiner deem expedient a telephone discussion to further the prosecution of the above application, applicants request that the Examiner contact the undersigned at her convenience.

Respectfully submitted,



Daniel A. Pearson (Reg. No. 58,053)
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, MA 02139-4242
Tel.: (617) 444-6790
Fax.: (617) 444-6483